https://www.barrons.com/articles/fda-nash-drugs-intercept-stock-ada234af
0
0
5/22/23 at 4:55pm
Organization
Barron's
Author
Josh Nathan-Kazis
36 words
0
Comments
Intercept's obeticholic acid may not lead a pack of drugs to treat the liver condition known as nonalcoholic steatohepatitis, or NASH, but other candidates remain.
You are the first to view
Create an account
or login to join the discussion